An observational study in Peripheral Diabetic Neuropathy and Painful Diabetic Neuropathy, sponsored by Averitas Pharma, Inc.. Active, not recruiting at 10 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Averitas Pharma, Inc. (part of Grünenthal GmbH) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Diabetic Neuropathies with a site in United States — 12 open to participants now, 17 under way, none of them phase 3. Diabetic Neuropathies · United States.
Among the 158 studies in Diabetic Neuropathies with a site in United States, this one is the 6th largest by enrollment of the 11 observational ones that give a count, is one of 4 that started in 2025, is one of 11 observational ones, reaches primary completion later than 10 of the 16 other live ones, and was the 149th registered.
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
Browse Diabetic Neuropathies studies →12 of the 158 studies in Diabetic Neuropathies with a site in United States are open now. Recruiting first, the newest first:
Florida A&M University · Sites in United States
Ages 40–70
Carilion Clinic · Sites in United States
Ages 25–75
C5 Biomedical · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19–89
Axolotl Biologix · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 58 · Phase 3 26 · Phase 4 18
First in 1993; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 104 across 68 observational studies indexed under Diabetic Neuropathies.
Median enrollment 91 across the 145 interventional studies, 144 across the 11 observational. Of the 122 that completed or were terminated, 47 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 158 have an industry lead sponsor. The 10 most frequent:
This study is registered under Averitas Pharma, Inc., one of the names counted as Grünenthal GmbH. Under that name alone:
Averitas Pharma, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Grünenthal GmbH has 2 studies filed under Diabetic Neuropathies — fewer than ten, so there is no comparison to draw.
11 of the studies in Diabetic Neuropathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06674980C5 BiomedicalClinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs | 2026-11-22 |
| NCT04678895Dartmouth-Hitchcock Medical CenterLow-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy | 2026-12 |
| NCT07298408Florida A&M UniversityCannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study | 2026-12-31 |
| NCT07250828TriCity Research CenterEfficacy and Feasibility of BurstDR SCS in Painful Diabetic Neuropathy | 2027-01 |
| NCT06480786University of NebraskaSCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 158 studies in Diabetic Neuropathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this post-market observational study is to provide real-world evidence to support the repeated use of QUTENZA in patients with PDPN and to evaluate the potential for pain and concomitant medication use reduction.
The patients for inclusion in the study are those with PDPN as assessed by the Douleur Neuropathique 4 Interview (DN4I) assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive repeat applications of the capsaicin 8% topical system every 12 weeks (up to 3 applications).
Drug: Capsaicin 8%
Repeat applications every 12 weeks in patients with PDPN of the feet.
Change (%) in pain intensity post QUTENZA administrations
The pain intensity score from baseline will be compared to the average weekly pain intensity score between weeks 2-12 post each QUTENZA application (up to 3 applications).
Time frame: Baseline, weeks 2-12 Post-Admin
Change (%) in overall scores for Patient-Report Outcomes Measurement Information System (PROMIS)-29
The baseline PROMIS-29 scores for all domains will be compared to the PROMIS-29 scores assessed at 12 weeks post-each QUTENZA application (up to 3 applications).
Time frame: Baseline, week 12 Post-Admin
Total number of patients who completed each QUTENZA treatment.
Analysis of the number of patients who completed repeated (2 or 3) QUTENZA applications.
Time frame: week 12 Post-Admin
Change (%) of concomitant medications at baseline and 12 weeks after each treatment
The change in utilization of pharmaceutical drug by medication, pharmacology class, dose, and frequency of use for drugs for PDPN, documented by collecting Concomitant medications including indication (for PDPN, for other reasons, and for temporary rescue use for PDPN) and dose
Time frame: through study completion, an average of 36 weeks
Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.
Of 19 observational studies under Diabetic Neuropathies, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 47. This study's planned 23 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.